<DOC>
	<DOC>NCT02806141</DOC>
	<brief_summary>This study is planned to compare the clinical efficacy and safety of aerosolized plus intravenous colistin vs. intravenous colistin as adjunctive therapy for the treatment of ventilator-associated pneumonia (VAP) due to pandrugs-resistant (PDR) Acinetobacter baumannii in the neonates.</brief_summary>
	<brief_title>Aerosolized Plus Intravenous vs. Intravenous Colistin for VAP Due to Pandrugs-resistant A. Baumannii in Neonates</brief_title>
	<detailed_description>This study will evaluate the neonates with VAP due to PDR-Acinetobacter baumannii who receive aerosolized plus intravenous colistin compare with intravenous colistin as adjunctive therapy. The efficacy and safety after study will be evaluated.</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
	<mesh_term>Colistin</mesh_term>
	<criteria>Neonates who are admitted to the neonatal intensive care unit, Hat Yai Hospital during the study period. Neonates who were complicated with VAP due to PDRAcinetobacter baumannii susceptible to colistin (by minimal inhibitory concentration (MIC) &lt; 2 mcg/dL). Neonates who have a major anomaly or chromosomal abnormality. Neonates who receive colistin prior 7 days prior to study. Neonates who have a significant renal dysfunction defined as a serum creatinine (SCr) &gt;1.5 mg/dL or a decrease in urine output to &lt; 1 mL/kg/h;</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Days</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Aerosolized colistin</keyword>
	<keyword>Intravenous colistin</keyword>
</DOC>